DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Discovery of Sirolimus Sensitive Biomarkers in Blood

Phase 2

Completed

Conditions: Lymphangioleiomyomatosis

Interventions: Drug: Sirolimus 2mg

First Posted Date: 2017-10-09

Last Posted Date: 2025-04-02

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 33

Registration Number: NCT03304678

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments

Not Applicable

Recruiting

Conditions: Obesity

Interventions: Device: Bluetooth-enabled glucometer
Device: Bluetooth-enabled scale
Device: Global Positioning System (GPS) Device
Device: Step it Up mobile app

First Posted Date: 2017-09-20

Last Posted Date: 2025-05-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 325

Registration Number: NCT03288207

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)

Completed

Conditions: Coronary Disease
Myocardial Ischemia
Arteriosclerosis
Coronary Artery Disease
Arterial Occlusive Diseases

First Posted Date: 2017-08-18

Last Posted Date: 2025-01-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 36

Registration Number: NCT03253692

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States

Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Plerixafor

First Posted Date: 2017-07-24

Last Posted Date: 2023-09-21

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 15

Registration Number: NCT03226691

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Extracellular RNAs in Relation to Cardiometabolic Risk

Completed

Conditions: Subclinical Atherosclerotic Cardiovascular Disease
Obesity
Blood Pressure

First Posted Date: 2017-07-21

Last Posted Date: 2023-12-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 4495

Registration Number: NCT03225196

Locations: 🇺🇸
Framingham Heart Study, Framingham, Massachusetts, United States

RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2

Completed

Conditions: Cardiovascular Disease
Hypertension

First Posted Date: 2017-07-21

Last Posted Date: 2022-06-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1700

Registration Number: NCT03225183

Locations: 🇺🇸
Framingham Heart Study, Framingham, Massachusetts, United States

Eltrombopag for People With Fanconi Anemia

Phase 2

Active, not recruiting

Conditions: Fanconi Anemia

Interventions: Drug: Eltrombopag

First Posted Date: 2017-07-02

Last Posted Date: 2025-02-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 25

Registration Number: NCT03206086

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2

Active, not recruiting

Conditions: Leukemia, Chronic Lymphatic
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphocytic Leukemia, Chronic, B Cell
Lymphocytic Leukemia, Chronic, B-Cell
B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytic Leukemia, Chronic
Chronic Lymphocytic Leukemia
Leukemia, Chronic Lymphocytic, B-Cell
Leukemia, Lymphocytic, Chronic

Interventions: Drug: Ibrutinib
Drug: Fludarabine
Drug: Pembrolizumab

First Posted Date: 2017-06-29

Last Posted Date: 2023-11-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 15

Registration Number: NCT03204188

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

Phase 1

Recruiting

Conditions: Hypo-Plastic MDS
Myelodysplastic Syndrome (MDS)
Severe Aplastic Anemia

Interventions: Biological: Omidubicel (former CordIn)
Device: Miltenyi CliniMACS(R) CD34 Reagent System

First Posted Date: 2017-06-02

Last Posted Date: 2025-05-08

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 37

Registration Number: NCT03173937

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires

Not Applicable

Suspended

Conditions: Structural Heart Disease
Pulmonary Artery Hypertension
Congenital Heart Disease

Interventions: Procedure: MRI Heart guidewire catheterization

First Posted Date: 2017-05-15

Last Posted Date: 2025-05-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 22

Registration Number: NCT03152773

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy